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Apparent 
Triclabendazole-
Resistant Human 
Fasciola hepatica 
Infection, the 
Netherlands
To the Editor: In December 
2007, a 71-year-old sheep farmer 
sought care with a 4-month history of 
intermittent right upper quadrant pain, 
night sweats, anorexia, and a 5-kg 
weight loss. His medical history was 
unremarkable, and he had not traveled 
outside the Netherlands for ≈30 years. 
Physical examination revealed no 
abnormalities.
Blood tests showed an elevated 
erythrocyte sedimentation rate of 
35 mm/h (reference 1–15 mm/h), 
normocytic anemia (hemoglobin 7.0 
mmol/L [reference 8.5–11 mmol/L]), 
and eosinophilia (2.5 × 109 cells/L 
[reference 0.0–0.5 × 109 cells/L]). 
Levels of alkaline phosphatase, 
γ-glutamyl transferase, and alanine 
aminotransferase were elevated (146 
U/L [reference 10–120 U/L], 143 U/L 
[reference 5–50 IU/L], and 54 U/L 
[reference 0–45 U/L], respectively). 
Levels of bilirubin and aspartate 
aminotransferase were normal. 
Computed tomography of the liver 
showed several irregularly shaped 
low-attenuating lesions ranging in size 
from 1 to 4 cm. High titers of IgG (640 
[cutoff 40], determined by enzyme 
immunoassay) against Fasciola 
hepatica were detected. Subsequently, 
F. hepatica eggs were detected in fecal 
samples.
The patient, who spontaneously 
had become asymptomatic shortly 
after seeking care, was treated 
unsuccessfully with the benzimidazole 
derivative triclabendazole (TCBZ) on 
3 separate occasions during the next 
2 years. He was fi rst treated with 
a single dose of 10 mg/kg TCBZ 
(Fasinex suspension; Novartis Animal 
Health Ltd., Surrey, UK), then with 
2 doses 24 hours apart, and on the 
last occasion with 2 doses of TCBZ 
(Egaten; Sipharm Sisseln AG, Sisseln, 
Switzerland) 10 mg/kg 12 hours apart; 
the last 4 treatments were taken with 
food. Feces remained positive for F. 
hepatica eggs after each treatment. 
IgG titers remained positive (320, by 
enzyme immunoassay), and fl ukes 
could be visualized by ultrasound 
in the gallbladder and common bile 
duct (Figure). Thereafter, the patient 
was treated with nitazoxanide (500 
mg 2×/d for 7 days); however, fecal 
samples remained positive for F. 
hepatica eggs. Lastly, after recent 
experiments of a combination therapy 
in a rat model (1), we treated the 
patient with TCBZ (Egaten, 10 mg/
kg) combined with ketoconazol 10 
mg/kg taken with food. Still, his feces 
remained positive for F. hepatica eggs.
Fascioliasis is a zoonotic disease 
caused by the foodborne trematode F. 
hepatica or F. gigantica, which has a 
complex life cycle and mainly affects 
sheep and cattle (2). Eggs of the adult 
worms (2–4 cm) that live in the bile 
ducts of the fi nal host are excreted 
in the feces and develop into larvae 
(miracidia) in water. The miracidia 
then penetrate, and further develop in, 
snails of the family Lymnaeidae. Free-
swimming cercariae exit the snail and 
attach to aquatic vegetation, where 
they encyst as metacercariae. After 
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ingestion by the host, they excyst in 
the intestine and migrate through the 
intestinal wall to the liver, where they 
mature into adult fl atworms that reside 
in the bile ducts (2).
Fascioliasis affects millions of 
humans worldwide (3); however, 
fascioliasis acquired in the Netherlands 
has been reported only sporadically 
(4), even though F. hepatica infection 
in sheep and cattle is prevalent there 
(5). The patient in this report had 
not eaten watercress or other aquatic 
plants and had not ingested ditchwater. 
However, he had worked in and 
around ditches on farms in the area, 
admitted chewing grass sporadically, 
and might have occasionally ingested 
vegetables previously fertilized with 
livestock manure. The patient remains 
asymptomatic but infected.
TCBZ is the treatment of choice 
for fascioliasis. In a review by Keiser 
et al. (6), the effi cacy of treatment 
with TCBZ was shown to yield egg 
clearance in 78%–100% of patients 
after 1 dose of 10 mg/kg and in 92%–
100% after 2 doses of 10 mg/kg each 
12 or 24 hours apart. In livestock, 
TCBZ resistance is being reported 
increasingly (7). Mass treatment 
of sheep and cattle with TCBZ 
(Fasinex) or in combination with other 
anthelmintic drugs is common in the 
Netherlands (L. Moll, pers. comm.), 
and the fi rst cases of resistance were 
described in 1998 in sheep and cattle 
in the province of North Holland, the 
area of residence of the patient reported 
in this study (8,9). During 1998–2004, 
resistance to TCBZ, proven by fecal 
egg count reduction tests, was found 
on 14 farms in the same area (5).
The fi ndings in this case are most 
likely explained by TCBZ resistance, 
although we note that repeated TCBZ 
courses are not 100% effective against 
fascioliasis (6). Re-infection can be 
excluded because fecal samples were 
tested for eggs 1–3 months after each 
treatment. This description of apparent 
TCBZ-resistant fascioliasis in a 
human highlights the human health 
implications of (massive) anthelmintic 
use in livestock.
Further studies on TCBZ 
resistance and on therapeutics for 
fascioliasis need to be conducted. 
In addition, the role of antimicrobial 
drugs in the treatment of livestock 
needs to be more rigorously evaluated.
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Figure. A) Ultrasound of the liver of a patient with Fasciola hepatica infection, the 
Netherlands. B) Drawing of A; depicted are the liver (white), the common bile duct (gray), 
and the portal vein (black). A fl uke (white), measuring 2.5–3 cm long, is identifi ed in the 
common bile duct.
